B. Egerdie

发表

Morphology of gel state phosphatidylethanolamine and phosphatidylcholine liposomes: a negative stain electron microscopic study.

M. Singer, B. Egerdie, 1982, Chemistry and physics of lipids.

Sarcopenia during androgen-deprivation therapy for prostate cancer.

F. Saad, T. Tammela, C. Goessl, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

L. Stothers, J. Gajewski, S. Herschorn, 2010, The Journal of urology.

Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.

F. Saad, B. Egerdie, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

F. Saad, T. Tammela, C. Goessl, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

F. Saad, T. Tammela, C. Goessl, 2009, The Journal of urology.

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases

L. Fallowfield, C. Cleeland, D. Patrick, 2015, Supportive Care in Cancer.

Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy.

F. Saad, T. Tammela, G. Ellis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC).

F. Saad, T. Tammela, C. Goessl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

L. Stothers, J. Gajewski, S. Herschorn, 2011, Current medical research and opinion.

Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

S. Denmeade, B. Egerdie, R. Merchant, 2011, European urology.

Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.

T. Morris, Y. Fradet, J. Armstrong, 2007, European urology.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial

M. Lucia, N. Fleshner, R. Rittmaster, 2012, The Lancet.

A real‐life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis

J. Nickel, J. Downey, B. Egerdie, 2009, BJU international.

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

F. Saad, J. Chin, T. Tammela, 2012, The Lancet.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

F. Saad, T. Tammela, C. Goessl, 2009, The New England journal of medicine.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

L. Fallowfield, C. Cleeland, D. Patrick, 2013, Supportive Care in Cancer.

A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.

M. Marberger, E. Chartier-Kastler, J. Grosse, 2013, European urology.

Development of a 90‐Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection

M. Meng, Y. Lotan, W. Sexton, 2017, The Journal of urology.

A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.

J. Nickel, R. Evans, L. Mackenzie, 2016, The Journal of urology.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial

M. Lucia, N. Fleshner, R. Rittmaster, 2012, The Lancet.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial

M. Lucia, N. Fleshner, R. Rittmaster, 2012 .

EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DENOSUMAB ON BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN-DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER

C. Goessl, B. Leder, Matthew R. Smith, 2009 .

A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY

F. Saad, T. Tammela, C. Goessl, 2009 .

78 EFFECT OF BASELINE CHARACTERISTICS ON RELATIVE RISK OF PROSTATE CANCER PROGRESSION IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT (REDEEM) TRIAL

M. Lucia, N. Fleshner, R. Rittmaster, 2011 .

7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer

F. Saad, T. Tammela, C. Goessl, 2009 .

Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

S. Denmeade, B. Egerdie, R. Merchant, 2011, European urology.

Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS

E. Chartier-Kastler, P. Denys, B. Brucker, 2018, Neurology.

Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer

Sanjay G. Patel, Y. Lotan, V. Reuter, 2021, BJU international.

A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.

J. Nickel, R. Evans, L. Mackenzie, 2016, The Journal of urology.